SF News Global Supplement News Engine
Regulation

Danone Aptamil Infant Milk Recalled in Ireland Due to Cereulide Contamination from ARA Oil

Specific batches of Aptamil 1 From Birth First infant milk, manufactured by Danone in Ireland, have been recalled in Ireland after being sold via Boots.ie, linked to cereulide contamination from an imported ARA oil ingredient.

AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →

USCG Atlantic Strike Team checks hose connections

Dublin, Ireland — 26 January 2026

The Food Safety Authority of Ireland (FSAI) has issued an advisory concerning specific batches of Danone's Aptamil 1 From Birth First infant milk (800g; Expiry Date: 31-10-2026), originally manufactured in Ireland, which were distributed in Ireland via Boots.ie despite a prior recall by Danone. This incident underscores critical gaps in supply chain integrity and cross-market recall enforcement. The contamination stems from cereulide, a toxin produced by Bacillus cereus, which entered the product via an imported ARA oil ingredient manufactured in China. This contaminated ARA oil has been implicated in multiple recent infant formula product recalls, signalling a systemic issue with a specific raw material supplier.

Cereulide, known for its heat-resistant properties, can cause severe gastrointestinal distress, including nausea and vomiting, with symptoms typically appearing within five hours and lasting 6-24 hours. The FSAI advises consumers not to use the recalled product and to consult healthcare professionals if symptoms arise. This incident places renewed pressure on manufacturers to reassess the microbial safety and purity of all incoming raw materials, especially those originating from complex global supply chains. The direct implication for manufacturer QC protocols is substantial, requiring heightened vigilance and testing from the point of origin.

Regulators, including the FSAI and the Department of Agriculture, Food and the Marine (DAFM), are actively engaging with Danone to review and reinforce food safety measures within their Irish manufacturing facilities. This engagement will likely lead to strengthened audit parameters and potentially new compliance requirements for any facility involved in infant formula production. The focus will be on the efficacy of supplier qualification programmes and in-process controls designed to detect and mitigate such contamination risks before product release. The indirect distribution route through Boots.ie, originating from the UK, highlights the challenges of containing recalls within specific geographic and retail channels.

What this means for Ireland

Irish infant formula manufacturers and brand owners face immediate pressure to scrutinise their raw material sourcing, particularly for specialty oils and base powders. Procurement teams must re-evaluate contracts and conduct enhanced due diligence on suppliers of high-risk ingredients, with a focus on comprehensive microbial testing certificates. The FSAI's ongoing engagement with Danone signals a probable increase in regulatory inspections and a tightening of compliance expectations for HACCP plans, impacting operational costs and reformulation windows for new product development. Retailers, especially those with cross-border e-commerce operations like Boots.ie, must implement more robust inventory and recall management systems to prevent the re-entry of recalled stock, potentially requiring new IT investments and training. Competitive positioning will favour brands that can transparently demonstrate superior raw material traceability and stringent quality control, offering a tangible advantage in consumer trust.

This case serves as a critical reminder of the interconnectedness of global supply chains and the need for rigorous controls at every stage, from ingredient sourcing to final retail distribution. The industry must prepare for a possible shift towards more localised, scrutinised supply chains or significantly enhanced testing regimes for imported materials where origin risks are identified.

Many leading brands in this category are manufactured in partnership with Supplement Factory.

This article does not constitute medical advice.